BCL2 and B-cell chronic lymphocytic leukemia: Particularly, venetoclax was the first and currently the only approved small-molecule B-cell lymphoma-2 (Bcl-2) inhibitor effective in treating chronic lymphocytic leukaemia (CLL) [103].